Cocoa Flavanol Supplementation in Raynaud's Phenomenon
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03815162 |
Recruitment Status :
Completed
First Posted : January 24, 2019
Last Update Posted : November 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Raynaud Phenomenon | Dietary Supplement: High Flavanol Cocoa extract Dietary Supplement: Alkalised cocoa | Not Applicable |
Primary Raynaud's phenomenon (PRP) is characterised by periodic vasospasm of the fingers and toes precipitated by exposure to cold or emotional stimuli and stress. Previous studies have demonstrated that underlying this condition there can be vascular endothelium dysfunction. Pharmacological interventions used to relieve symptoms and complications in PRP include drugs targeted at increasing nitric oxide (NO; transdermal nitrates) levels. Cocoa derived products, rich in the phytonutrients 'flavanols', have been shown to increase the bioavailability of NO at the vascular endothelium and promote vasodilation, which may address an underlying cause of PRP and mitigate symptoms. Previous work carried out in the research group has indicated that the acute consumption of cocoa does not compromise the counter-regulatory responses to localised cold exposure in those with PRP.
30 individuals with PRP will be recruited. Those interested in taking part will attend a medical screening and consent visit. If recruited, a participant number will be assigned to them sequentially and they will be randomised to either experimental or control group, with neither the participants nor the research team knowing which group they have been allocated to. Participants will be asked to complete a diet diary before attending 4 further visits over a period of 3 months.
Visit 1 (pre-intervention) and 4 (end of intervention); immediately on arrival, participants will be asked to lie semi-supine on a hospital bed. Skin temperature (surface thermocouples) and 'core' temperature (infrared tympanic thermometer) will start to be recorded to identify when these parameters have stabilized in room temperature (set at 25oC). Blood pressure will be taken using an arm cuff. Then a Finometer cuff will be attached to the left middle finger to record cardiovascular parameters (Blood pressure /heart rate/ cardiac output) and a laser Doppler probe will be attached to the dorsum of both index fingers to assess skin blood flow. Once the finger skin temperature has remained stable for 6 minutes, baseline Finometer and laser Doppler measurements will be recorded and the skin and 'core' temperature will be noted. Then, the right hand will be placed in a temperature regulated box which is set at an air temperature of 0oC. The hand will be cooled to a finger skin temperature of 15oC, then the box temperature will be modified to maintain the skin temperature at 15oC. The time that it takes for the skin temperature on the fingers to reach 15oC will be recorded. With the finger skin temperature stable at 15oC, Finometer and laser Doppler measurements will be repeated and the 'core' temperature at this point noted. Then, the hand will be removed from the chamber, and allowed to equilibrate in room temperature. The time taken for the skin temperature to reach stability will be recorded, as will the absolute temperature that it stabilises to. Measures above will be repeated once hand temperature is stable. Once these measures have been made, all equipment will be removed and a 15ml blood sample will be taken (for epicatechin, glucose and insulin analysis). The participant will be asked to complete 3 questionnaires (SF-36, Raynaud's symptoms and a food frequency questionnaire). Participants will also return a 4-day diet diary at visits 1 and 4, and their symptom diary at visit 4.
Visits 2 (end of month 1) and 3 (end of month 2); participants will return a 4-day diet diary, symptom diary and any unused capsules. They will also have a resting blood pressure measurement made, weight measured and be asked to complete 3 questionnaires (SF-36, Raynaud's symptoms and a food frequency questionnaire).
At the end of Visits 1, 2 and 3, participants will be given a months' supply of capsules, a symptom diary and a diet diary (to be completed in the week prior to the next visit).
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 27 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Double-blinded, placebo controlled study. Block randomised with equal allocation of participants between groups. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Opaque capsules of equal size and appearance presented in similar bottles labelled only by a code. Code to product information is held by the manufacturer and un-blinding of the PI will only occur once the study analysis has been completed or in the event of a serious adverse event occurring. |
Primary Purpose: | Prevention |
Official Title: | Pilot Study to Investigate the Effect of Cocoa Flavanols on Symptoms in Primary Raynaud's Phenomenon |
Actual Study Start Date : | October 16, 2018 |
Actual Primary Completion Date : | April 30, 2020 |
Actual Study Completion Date : | July 31, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: High Flavanol Cocoa extract
278mg total flavanols (38.3mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (836 mg total flavanols; 115mg epicatechin) for 3 months
|
Dietary Supplement: High Flavanol Cocoa extract
Experimental group |
Placebo Comparator: Alkalised cocoa
0mg total flavanols (0mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (0mg total flavanols; 0mg epicatechin) for 3 months
|
Dietary Supplement: Alkalised cocoa
Control group |
- Vasospasm [ Time Frame: 3 months ]frequency of vasospasm
- Severity of vasospasm symptoms [ Time Frame: 3 months ]visual analogue score for pain associated with each vasospasm occasion. Participants indicate pain intensity by placing a vertical line on a 100mm horizontal line where the start of the line (left-hand side; 0mm) represents 'no pain' and the end of the line (right-hand side; 100mm) represents 'most severe pain'. Distance of the vertical line from 0 provides the visual analogue score. A lower score indicates a more favourable outcome.
- Duration of vasospasm symptoms [ Time Frame: 3 months ]duration that symptoms persist for on each vasospasm occasion
- Raynaud's Condition score [ Time Frame: 3 months ]Assessment of Raynaud's symptoms using the validated Raynaud's Condition Score. This is a 1 to 10 Likert scale, with 0 representing 'no difficulty' and 10 indicating 'extreme difficulty' with symptoms; collected daily for 3 months, a lower score indicates a more favourable outcome.
- Blood pressure [ Time Frame: pre-intervention ]blood pressure measured by automated oscillometric blood pressure
- Blood pressure [ Time Frame: 4 weeks after starting intervention ]blood pressure measured by automated oscillometric blood pressure
- Blood pressure [ Time Frame: 8 weeks after starting intervention ]blood pressure measured by automated oscillometric blood pressure
- Blood pressure [ Time Frame: 12 weeks after starting the intervention ]blood pressure measured by automated oscillometric blood pressure
- Dietary polyphenol intake [ Time Frame: pre-intervention ]estimation of dietary polyphenols made by food frequency questionnaire
- Dietary polyphenol intake [ Time Frame: 4 weeks after starting intervention ]estimation of dietary polyphenols made by food frequency questionnaire
- Dietary polyphenol intake [ Time Frame: 8 weeks after starting intervention ]estimation of dietary polyphenols made by food frequency questionnaire
- Dietary polyphenol intake [ Time Frame: 12 weeks after starting the intervention ]estimation of dietary polyphenols made by food frequency questionnaire
- Ambient skin temperature [ Time Frame: pre-intervention ]skin temperature of a finger exposed to an environmental temperature of 25oC, before cooling
- Ambient skin temperature [ Time Frame: 12 weeks after starting the intervention ]skin temperature of a finger exposed to an environmental temperature of 25oC, before cooling
- Ambient skin blood flow [ Time Frame: pre-intervention ]finger blood flow (measured using laser Doppler flowmetry) when exposed to an environmental temperature of 25oC, before cooling
- Ambient skin blood flow [ Time Frame: 12 weeks after starting the intervention ]finger blood flow (measured using laser Doppler flowmetry) when exposed to an environmental temperature of 25oC, before cooling
- Skin temperature response to acute cooling [ Time Frame: pre-intervention ]The time taken for skin temperature of the finger to stabilise in response to localised cooling (in an air temperature of 0oC)
- Skin temperature response to acute cooling [ Time Frame: 12 weeks after starting the intervention ]The time taken for skin temperature of the finger to stabilise in response to localised cooling (in an air temperature of 0oC)
- Skin blood flow response to acute cooling [ Time Frame: pre-intervention ]Finger Skin blood flow; measurement (using laser Doppler flowmetry) made once finger skin temperature has stabilised in response to localised cooling (in an air temperature of 0oC)
- Skin blood flow response to acute cooling [ Time Frame: 12 weeks after starting the intervention ]Finger Skin blood flow; measurement (using laser Doppler flowmetry) made once finger skin temperature has stabilised in response to localised cooling (in an air temperature of 0oC)
- Skin temperature response to re-warming [ Time Frame: pre-intervention ]The time taken for skin temperature of finger to stabilise in an environmental temperature of 25oC following localised cooling (in an air temperature of 0oC)
- Skin temperature response to re-warming [ Time Frame: 12 weeks after starting the intervention ]The time taken for skin temperature of finger to stabilise in an environmental temperature of 25oC following localised cooling (in an air temperature of 0oC)
- Skin temperature after re-warming [ Time Frame: pre-intervention ]skin temperature that a finger exposed to an environmental temperature of 25oC stabilises to after localised cooling
- Skin temperature after re-warming [ Time Frame: 12 weeks after starting the intervention ]skin temperature that a finger exposed to an environmental temperature of 25oC stabilises to after localised cooling
- Quality of life score [ Time Frame: pre-intervention ]Assessed using SF-36 questionnaire. Responses are coded and normalised to the UK population, as per standard methods, and a score for mental and physical health calculated; a higher score indicating a more favourable outcome
- Quality of life score [ Time Frame: 4 weeks after starting intervention ]Assessed using SF-36 questionnaire. Responses are coded and normalised to the UK population, as per standard methods, and a score for mental and physical health calculated; a higher score indicating a more favourable outcome
- Quality of life score [ Time Frame: 8 weeks after starting intervention ]Assessed using SF-36 questionnaire. Responses are coded and normalised to the UK population, as per standard methods, and a score for mental and physical health calculated; a higher score indicating a more favourable outcome
- Quality of life score [ Time Frame: 12 weeks after starting the intervention ]Assessed using SF-36 questionnaire. Responses are coded and normalised to the UK population, as per standard methods, and a score for mental and physical health calculated; a higher score indicating a more favourable outcome
- Attrition rate [ Time Frame: 2 years ]Number of participants completing the protocol as a proportion of those who were randomised to the study
- Adverse events [ Time Frame: 3 months ]Any injury, accident or illness experienced over the intervention period will be documented
- Recruitment rate [ Time Frame: 2 years ]number of people volunteering to take part in the study as a proportion of those expressing initial interest
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Experience symptoms of Primary Raynaud's Phenomenon, with >1 attack / week through the winter months
- Daily consumption of caffeine containing foods/drinks.
- BMI <27kg/m2
Exclusion Criteria:
- pregnant or breast feeding (women only),
- clinically significant metabolic or endocrine abnormalities
- fasting glucose >6.5mmol/l,
- taking Bosentan, aspirin, dipyridamole, heparin or transdermal nitrates,
- herbal supplement use,
- food allergies related to the investigational product (cocoa, peanuts, milk),
- sensitivity to methylxanthines (e.g. caffeine, theobromine).
- Presence or history of digital ulceration,
- blood parameters suggesting secondary Raynaud's,
- history of migraines
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03815162
United Kingdom | |
David Greenfield Human Physiology Laboratories | |
Nottingham, Notts, United Kingdom, NG72UH |
Study Director: | Ian A Macdonald, PhD | University of Nottingham |
Responsible Party: | Elizabeth Simpson, Senior Research Fellow, University of Nottingham |
ClinicalTrials.gov Identifier: | NCT03815162 |
Other Study ID Numbers: |
112-1809 |
First Posted: | January 24, 2019 Key Record Dates |
Last Update Posted: | November 4, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual data will not be shared with other researchers |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
cocoa flavanols |
Raynaud Disease Livedoid Vasculopathy Thrombosis Embolism and Thrombosis Vascular Diseases |
Cardiovascular Diseases Peripheral Vascular Diseases Skin Diseases, Vascular Skin Diseases |